Ziihera Combinations Show Three-Year Survival in Advanced Gastroesophageal Cancer
At ESMO 2026, results for Ziihera plus tislelizumab and chemotherapy showed nearly 40% of patients alive at three years and median overall survival of 27 months, irrespective of PD-L1 status. Ziihera plus chemotherapy also delivered a statistically significant and clinically meaningful overall-survival benefit.
Story updates
02:16:25 PM UTC
SquawkNews
Jazz Pharmaceuticals reported Phase 3 HERIZON-GEA-01 results: Ziihera plus chemo cut risk of death by 24% vs trastuzumab plus chemo, and nearly 40% on Ziihera+tislelizumab+chemo were alive at three years.Material DetailsContext by AI AnalystThis is late-cycle confirmation, reinforcing FDA-approved…